Litcius/Paper detail

A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness

Takayuki Yoshino, Naushin Hooda, Diana Younan, Kei Muro, Kohei Shitara, Volker Heinemann, Bert H. O’Neil, F. Rivera Herrero, Marc Peeters, Junpei Soeda, Mina Suh, Heidi Reichert, Khalid Mezzi, Jon P. Fryzek, Victoria Chia, Marko Rehn, Sebastian Stintzing

2024European Journal of Cancer27 citationsDOI

Topics & Concepts

BevacizumabMedicineOncologyInternal medicineEpidermal growth factor receptorMeta-analysisColorectal cancerHead (geology)Cancer researchReceptorBiologyChemotherapyCancerPaleontologyColorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesColorectal and Anal Carcinomas
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness | Litcius